TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$179 Million

Revolution Medicines

Follow-on Offering

Bookrunner, July 2020

Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. Revolution Medicines defines frontier targets as proteins that play an important role in cancer and for which there is either: (1) no approved drug that directly inhibits it, or (2) one or more approved drugs that directly inhibit it but through a mechanism of action that may not enable suppression of the full range of its biologic contributions to cancer. The Company’s most advanced product candidate, RMC-4630, is a potent and selective inhibitor of SHP2, based on preclinical evidence. SHP2 is a central node in the RAS signaling pathway. In collaboration with Sanofi, Revolution Medicines is evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program.